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Abstract
Background: Venous thromboembolism is a common, fatal, and costly injury which complicates major surgery in
older adults. The American College of Chest Physicians recommends high potency prophylaxis regimens for
individuals undergoing total hip or knee replacement (THR or TKR), but surgeons are reluctant to prescribe them
due to fear of excess bleeding. Identifying a high risk cohort such as older adults with comorbidities and co-
occurring comorbidities who might benefit most from high potency prophylaxis would improve how we currently
perform preoperative assessment.
Methods: Using the Nationwide Inpatient Sample, we identified older adults who underwent THR or TKR in the
U.S. between 2003 and 2006. Our outcome was VTE, including any pulmonary embolus or deep venous
thrombosis. We performed multivariate logistic regression analyses to assess the effects of comorbidities on VTE
occurrence. Comorbidities under consideration included coronary artery disease, congestive heart failure (CHF),
chronic obstructive pulmonary disease (COPD), diabetes, and cerebrovascular disease. We also examined the
impact of co-occurring comorbidities on VTE rates.
Results: CHF increased odds of VTE in both the THR cohort (OR = 3.08 95% CI 2.05-4.65) and TKR cohort
(OR = 2.47 95% CI 1.95-3.14). COPD led to a 50% increase in odds in the TKR cohort (OR = 1.49 95% CI 1.31-1.70).
The data did not support synergistic effect of co-occurring comorbidities with respect to VTE occurrence.
Conclusions: Older adults with CHF undergoing THR or TKR and with COPD undergoing TKR are at increased risk
of VTE. If confirmed in other datasets, these older adults may benefit from higher potency prophylaxis.
Background
Medical injury, or harm associated with a therapeutic or
diagnostic intervention [1], commonly complicates
major surgery [2]. Age alone confers a small effect on
postoperative injury but medical comorbidities and
co-occurring comorbidities contribute substantially.
Co-occurring comorbidities, that is, 2 comorbidities
which frequently occur together, are part of a larger
phenomenon of multiple morbidity [3].
Venous thromboembolism (VTE) is a common, often
fatal, and costly injury which complicates major surgery
in older adults. VTE is particularly common following
total hip and knee replacement (THR and TKR), with
venographic rates of up to 60% without prophylaxis [4].
Newer, more potent prophylaxis regimens including the
synthetic pentasacchride fondaparinux and twice daily
dosing of enoxaparin, a low molecular weight heparin,
offer the ability to significantly reduce the risk of VTE.
Their wide spread adoption has been slow, however,
given the increased risk of bleeding [5]. The ability to
identify a high risk cohort among older adults under-
going THR and TKR, who would potentially benefit
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ment in the way clinicians currently conduct preopera-
tive assessments.
Comorbidities such as congestive heart failure (CHF)
and chronic obstructive pulmonary disease (COPD) have
been associated with increased VTE risk in some studies
[6-8] but not in others [9,10]. The association with CHF
may relate to blood flow stasis which is part of Virchow’s
triad [11] of alteration in blood flow (stasis), endothelial
injury, and alterations in blood constituents (hypercoa-
gulable factors). Similarly the association of COPD may
be explained through an immobility or stasis mechanism.
Newer evidence, in both surgical [6,7,9,10] and non-sur-
gical settings [12], suggests that atherosclerotic condi-
tions such as coronary artery disease (CAD) and
cerebrovascular disease (CVD) are also associated with
an increased risk of VTE. In general, these studies had a
small number of observations and/or did not focus on
discrete surgical procedures, making it difficult to draw
conclusions about modest but clinically important effects
on VTE of comorbidities for individual surgeries. The
combined effect of comorbidities, i.e., co-occurring
comorbidities, has been incompletely evaluated.
In this investigation, we assessed the Nationwide Inpa-
tient Sample to determine the risk of VTE in older
adults with prevalent comorbidities and co-occurring
comorbidities undergoing THR or TKR. We hypothe-
s i z e dt h a tC H F ,C A D ,C V D ,a n dC O P Dw o u l dp r e d i c t
increased risk of VTE. We also proposed that the joint
effect of co-occurring comorbidities – composed of
comorbidities with distinct pathogenesis, such as CAD
and COPD – would equal the sum of the component
effects or possibly exceed their sum, indicating a positive
interaction.
Methods
Data Sources and Study Sample
We used the Nationwide Inpatient Sample (NIS) from
2003-2006 for our analysis [13]. This work involves the
use of publicly available, archival information abstracted
from patient medical records and was approved by the
Institutional Review Board at the Boston University
Medical Center in Boston, Massachusetts. The NIS con-
tains information from hospital inpatient stays collected
at the state-level and then assembled by the Agency for
Healthcare Research and Quality (AHRQ) as part of the
Healthcare Utilization Project (HCUP). NIS includes
primary and secondary diagnoses, procedures, admission
and discharge status, patient demographics (gender, age,
race, median income, and residence zip code), expected
payment source, total charges, length of stay, and hospi-
tal characteristics (ownership, size, and teaching status).
We identified a cohort of patients (age 65 or older) who
underwent primary THR or TKR identified through
ICD-9-CM procedure codes 81.51 and 81.54. We
restricted our analysis to elective, primary THR and
TKR because we felt that non-elective surgery and revi-
sion joint surgery represented a distinct population with
different risks for VTE. We therefore excluded surgical
cases conducted in the setting of fracture, pelvic or
thigh infection, or removal of prior prosthesis, internal
fixation device, implant or graft consistent with earlier
work [14,15] conducted by members of our team.
Outcomes and Exposures
We determined VTE to have occurred if any one of
eight ICD-9-CM DVT codes, three PE codes, and two
non-specific VTE codes were present at discharge
(Additional file 1).
We included specific comorbidities based on evidence
of associations with VTE documented in the literature
or a known biological link to the outcomes These
included CAD, CHF, COPD, CVD, and diabetes.
Comorbidities and presence of obesity were coded as by
Elixhauser et al.[16] (Additional file 1). Multiple publica-
tions [17-19] have supported the use of the Elixhauser
comorbidity coding algorithms rather than the earlier
Charlson comorbidity index, including those looking at
discrete surgical procedures [20,21]. The accuracy of
coding of the comorbidities has been validated in multi-
ple publications [22,23]. We also examined co-occurring
comorbidities from the above mentioned comorbidities
if they had a prevalence of greater than 2% (given that
exposures occurring less frequently than 2% of the time
would be infeasible to study because of sample size
constraints).
Consistent with previous work [14,15,24], we evalu-
ated the effects of potentially confounding factors, i.e.,
race, insurance status, hospital surgical volume, obesity,
bi-laterality (two primary procedures during the same
surgery), chronic kidney disease, and hypercoagulable
state (including cancer and genetic predisposition), by
adding them, one at a time, to the crude model (with
comorbidity exposure, age group, and sex). If the addi-
tion of a given factor did not change the odds ratios for
the comorbidity exposure by more than 10%, it was
deleted from the final model.
Analysis
We calculated descriptive statistics and cross-tabular fre-
quencies for each outcome and comorbidity to determine
the shape of distributions, the extent of missing data, and
the presence of small frequencies of the discrete comor-
bidity levels. We examined comorbidities for statistical
interactions with each other. Specifically, we measured
whether prevalent combinations of comorbidities (as
defined above) produced statistically significant associa-
tions with VTE in multivariate models. Because we found
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of interpretability, we report the associations between
co-occurring comorbidities and outcomes using a catego-
rical comorbidity variable for both the THR and TKR
cohorts. We created a ten level categorical variable with a
separate, mutually exclusive, level for each of nine comor-
bidities or co-occurring comorbidities (with 1 additional
for all other combinations of two or more comorbidities).
While this limited the population size for each comorbid-
ity group, it allowed us to compare the risk of VTE for
groups of older adults with single or co-occurring comor-
bidities against a common reference group of older adults
without any of the nine comorbidities.
Finally, we built multivariate logistic regression models
to assess the independent effects of comorbidities. In
our analysis we retained age and sex in all models. For
remaining potential confounders, we retained any vari-
able that changed the effect estimate for any comorbid-
ity by more than 10%.
Results
In NIS 2003-2006, we identified 93,071 primary THR
and 223,600 primary TKR surgeries. Overall, the age of
older adults was evenly distributed into quartiles 65-69,
70-74, 75-79, and 80 or older. Sixty-three percent of
subjects were female. (Table 1) CAD, COPD, and dia-
betes alone occurred most frequently (9.8%, 8.6%, and
8.4%, respectively for the THR cohort). CVD and CHF
occurred much less frequently (0.6% and 1.2%, respec-
tively for the THR cohort). (Table 1) CAD with diabetes
was present in 2.5%, and CAD with COPD was present
in 1.9% of the THR cohort. (Table 1) Other combina-
tions occurred approximately 1% of the time. Similar
trends occurred in the TKR cohort.
VTE during the index hospitalization occurred 0.8% of
t h et i m ea f t e rT H Ra n d1 . 2 %o ft h et i m ea f t e rT K R .I n
the THR cohort, the rate of VTE ranged from 0.6% in
older adults with diabetes alone to 2.3% in older adults
with CHF alone; the rate of VTE in older adults without
any of the identified comorbidities was 0.7%. (Table 2)
Similarly, in the TKR cohort, this range was 1.1% to
2.6%; the rate of VTE in older adults without any of the
identified comorbidities was 1.1%. In multivariate analy-
sis CHF predicted a threefold increase in the odds of
VTE in the THR cohort (OR = 3.08 95% CI 2.05-4.65)
and a similar increase in the TKR cohort (OR = 2.47
95% CI 1.95-3.14). (Table 3) COPD predicted a 50%
increase in odds in the TKR cohort (OR = 1.49 95% CI
1.31-1.70). (Table 3)
We did not find any positive interactions between
comorbidities in our analysis. The combination of CAD
and CHF alone was associated with a twofold increase in
odds in both the THR and TKR cohort, an effect which
was smaller than for CHF alone. The combination of
diabetes and CAD was associated with a 39% decrease in
the odds of VTE only in the TKR cohort, an effect which
was smaller, i.e., more protective, than either comorbidity
alone. (Table 3) The six potential confounding factors
that we tested were deleted from the final model for lack
of confounding.
Discussion
We comprehensively examined the association of
comorbidities and co-occurring comorbidities and VTE
in a unique population of older adults undergoing pri-
mary total hip and knee replacement, high risk surgeries
for VTE. We found that the rates of VTE captured in
administrative data of older adults for the period imme-
diately following THR and TKR to be low at 0.8-1.2%.
Having CHF substantially increased the odds of VTE
after THR or TKR and having COPD somewhat
increased the odds of VTE after TKR. Co-occurring
comorbidities did not increase the risk of VTE beyond
their individual effects.
Comparison of our results with previous studies is
limited by differences in outcomes measured and popu-
lations studied. Gangireddy et al. [9] conducted one of
the largest studies to date using data from the Veterans
Affairs National Surgical Quality Improvement Program
(NSQIP), which included veterans undergoing nine dif-
ferent surgeries, including THR, between 1996 and
2001. After controlling for multiple preoperative and
postoperative clinical variables, a multivariate analysis
with 76,771 individuals showed that CHF and COPD
were not associated with increased rates of VTE. This
study supported our findings of the association between
diabetes and a slightly lower rate of VTE (OR = 0.75).
We also detected a 29% reduction in the risk of VTE in
patients undergoing THR with CVD. This result was not
statistically significant nor did we detect an association in
the knee population. There has been little evidence, how-
ever, regarding the relationship between CVD and post-
operative VTE. Prior work [12] has suggested a common
inflammatory pathway but this has not been evaluated
extensively in the postoperative setting. In our study the
association was not present for both knee and hip
c o h o r t sa n dw a sn o ts t a t i s t i cally significant. We plan to
re-assess this relationship in our future work.
Kikura et al. [6] examined 21,903 Japanese patients of
multiple ages and multiple surgery types and found that
history of acute myocardial infarction (AMI) was signifi-
cantly related (OR = 7.7 95% CI 1.7-34.7) to the devel-
opment of postoperative thrombotic events (including
repeat AMI). Although we did collect information about
the history of AMI in particular, we did not find an
association with CAD in general in our analysis. In a
cohort of 269 post-menopausal women undergoing
THR and TKR, Jaffer et al. [7] found a trend towards
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Page 3 of 7Table 1 Frequency counts (and row percentages) for selected variables and stratified by surgical procedure
Total Hip Replacement Total Knee Replacement
Age
65-69 yr 23405 (25.2) 63363 (28.3)
70-74 yr 24888 (26.7) 63608 (28.5)
75-79 yr 23316 (25.0) 54578 (24.4)
≥80 yr 21462 (23.1) 42051 (18.8)
Gender
Male 34578 (37.2) 78539 (35.1)
Female 58492 (62.8) 145061 (64.9)
Comorbid Diseases
Cerebrovascular Disease (CVD) alone 570 (0.6) 1356 (0.6)
Coronary Artery Disease (CAD) alone 9132 (9.8) 20017 (9.0)
Congestive Heart Failure (CHF) alone 1097 (1.2) 2746 (1.2)
Diabetes alone 7782 (8.4) 26740 (12.0)
Chronic Obstructive Pulmonary Disease (COPD) alone 7989 (8.6) 16836 (7.5)
CAD and CHF alone 731 (0.8) 1678 (0.8)
CAD and COPD alone 1731 (1.9) 3366 (1.5)
CAD and Diabetes alone 2320 (2.5) 7155 (3.2)
COPD and Diabetes alone 1181 (1.3) 3688 (1.7)
All other 2+ combinations 2725 (2.9) 6878 (3.1)
None of the above comorbidities 57813 (62.0) 133140 (59.4)
Median Length of Stay (days) 4 3
Table 2 Frequency counts for selected variables stratified by age and surgical procedure
Age Group
Hip Procedures Knee Procedures
Exposure 65-69
years of
age
70-74
years of
age
75-79
years of
age
≥80 years
of age
total 65-69
years of
age
70-74
years of
age
75-79
years of
age
≥80 years
of age
total
CVD alone 87 129 160 194 570 241 342 382 391 1356
CAD alone 1677 2269 2503 2683 9132 4065 5413 5608 4931 20017
CHF alone 143 209 277 468 1097 441 574 702 1029 2746
Diabetes alone 2159 2229 1935 1459 7782 8975 8197 6116 3452 26740
COPD alone 2110 2220 1949 1710 7989 4978 4873 4065 2920 16836
CAD and CHF alone 87 124 190 330 731 249 335 449 645 1678
CAD and COPD
alone
359 443 485 444 1731 726 937 978 725 3366
CAD and Diabetes
alone
512 673 632 503 2320 1909 2216 1906 1124 7155
COPD and Diabetes
alone
341 356 298 186 1181 1359 1148 772 409 3688
All other 2+
combinations
482 673 763 807 2725 1593 1904 1896 1485 6878
None of the above
comorbidities
15448 15563 14124 12678 57813 38827 37669 31704 24940 133140
Abbreviations: CAD = coronary artery disease, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, CVD = cerebrovascular disease.
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Page 4 of 7CHF predicting more postoperative VTE events (OR =
5.50 95% CI 0.94-43.3) but a trend towards COPD pre-
dicting fewer VTE events (OR = 0.42 95% CI 0.07-1.98).
The association of CHF and VTE may relate to blood
flow stasis as discussed earlier. Alternatively, CHF may
indicate a degree of immobility that was not measured
in the data we analyzed. Other comorbidities may also
contribute to the development of postoperative VTE but
their effects may have been attenuated by a selection
bias. Surgeons may select only the healthiest subset of
older adults with comorbidities for surgery. The absence
of positive interactions between frequently co-occurring
comorbidities (especially CAD and CHF) also suggests a
potential source of a selection bias. Older adults with
co-occurring comorbidities deemed to be suitable surgi-
cal candidates are presumably healthier in other ways
than other older adults with the same comorbidities.
In the case of COPD, we only detected an increase in
risk for older adults undergoing knee surgery. This
could be explained by the generally weak predictor
effect of COPD on VTE or it could be related to the
inherent differences between hip and knee surgery. Post-
operative mobility may be significantly less for hip sur-
gery and the effect of immobility in this group may
dwarf other predictors such as COPD. Future work
should examine the interaction between mobility and
surgery type in data where this information is available.
The association of CHF and COPD with postoperative
VTE has important implications. Although the Ameri-
can College of Chest Physicians currently recommends
high potency prophylaxis such as fondaparinux or
LMWH for all individuals undergoing THR and TKR
[4], surgeons are reluctant to prescribe these regimens,
fearing bleeding complications. Identification of a high
risk subset among a group of older adults already at
increased risk for VTE based on the surgery planned
would be an important improvement in the way we cur-
rently perform preoperative assessment. In addition to
the use of high potency prophylaxis, surgeons may also
use the risk information to incorporate other practices,
such as regional anesthesia, mechanical prophylaxis
devices, or stockings, aimed at lowering VTE rates.
There are limitations to the work we presented. Due
to the nature of the NIS administrative data we have
limited ability to capture VTE. A recent study [24], sug-
gests that administrative data capture only 58% of VTE
events. There is no evidence, however, to suggest that
the events indentified are differentially being diagnosed
in individuals with CHF or other comorbidities. In addi-
tion, we did not have access to medication information
including prophylaxis agent. A recent study by Cohen et
al. in 2008 [25] indicated that in the United States, only
48% of medical patients are receiving the recommended
ACCP prophylaxis and only 71% of surgical patients are
Table 3 Odds ratios (and 95% CIs) for exposures, adjusted
† for covariates and stratified by surgical procedure
HIP PROCEDURES KNEE PROCEDURES
Exposure VTE yes VTE no OR
† CIs VTE yes VTE no OR CIs
No Comorbidity 410 57403 1.00 (ref) 1458 131682 1.00 (ref)
CVD vs. 3 567 0.71 (0.23-2.23) 21 1335 1.42 (0.92-2.20)
CAD vs. 68 9064 0.98 (0.76-1.28) 257 19760 1.19 (1.04-1.37)
CHF vs. 25 1072 3.08 (2.05-4.65) 73 2673 2.47 (1.95-3.14)
Diabetes vs. 47 7735 0.85 (0.63-1.15) 282 26458 0.96 (0.85-1.10)
COPD vs. 60 7929 1.06 (0.81-1.39) 273 16563 1.49 (1.31-1.70)
CAD and CHF vs. 12 719 2.11 (1.18-3.78) 33 1645 1.86 (1.30-2.60)
CAD & COPD vs. 16 1715 1.25 (0.75-2.06) 52 3314 1.44 (1.09-1.90)
Diabetes & CAD vs. 18 2302 1.05 (0.65-1.69) 47 7108 0.61 (0.45-0.81)
Diabetes & COPD vs. 9 1172 1.09 (0.56-2.11) 36 3652 0.89 (0.64-1.24)
All other combinations 34 2691 1.69 (1.19-2.40) 111 6767 1.49 (1.23-181)
Age 65-69 163 23242 1.00 (ref) 734 62629 1.00 (ref)
Age 70-74 vs. Age 65-69 167 24721 0.96 (0.77-1.19) 751 62857 1.01 (0.91-1.12)
Age 75-79 vs. Age 65-69 172 23144 1.05 (0.84-1.30) 649 53929 1.00 (0.90-1.12)
Age ≥80 vs. Age 65-69 200 21262 1.30 (1.05-1.60) 509 41542 0.99 (0-89-1.11)
Females 411 58081 1.00 (ref) 1746 143315 1.00 (ref)
Males 291 34287 1.21 (1.04-1.41) 897 77642 0.94 (0.87-1.02)
Total observations 702 92369 2643 220957
†Associations adjusted in multivariate logistic regression for each comorbidity exposure as compared with the group with none of the listed comorbidities or co-
occurring comorbidities. All association were adjusted for age group and sex. We also assessed race, insurance status, hospital surgical volume, obesity, bi-
laterality (two primary procedures during the same surgery) and hypercoagulable state but deleted them from the final model for lack of confounding.
Abbreviations: CAD = coronary artery disease, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, CVD = cerebrovascular disease.
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Page 5 of 7receiving prophylaxis [25]. If comorbidities prompted
physicians to prescribe more potent prophylaxis in older
adults with CHF or other comorbidities, however, the
effects we observed would represent an underestimate
of the true effect. A recent survey [26] suggests that
orthopedic surgeons vary their prescribing patterns less
than 10% of the time when evaluating a patient with
cardiopulmonary disease. Future work should examine
the relationship between comorbidities and VTE while
controlling for prophylaxis agents in data where medica-
tion information is available.
We did not have information about events which took
place after hospitalization. Given that the median time
for development of DVT is 17 days for THR and 7 days
for TKR [27] and the median length of stay was 3 or 4
days for each surgery in our analysis, the associations
we present may not reflect the experience of older
adults who develop injury in the post discharge period.
Controlling for length of stay would not disentangle the
relation between these comorbidities and VTE and we,
therefore, did not control for it in our analysis. Length
of stay may very well be a surrogate for immobility and
stasis which are on the causal pathway of VTE develop-
ment. Alternatively, increased length of stay may also be
associated with VTE because of added time needed to
achieve therapeutic levels of warfarin. Even though NIS
data does not allow for measurement of the 30 or 90
day incidence of VTE, we believe that post discharge
rates of VTE events will be similarly disparate in indivi-
duals with compared to those without comorbidities. In
the future we plan to confirm these associations in data
where this information is available.
Administrative data are susceptible to upcoding where
medical coders assign a diagnosis that may have only
been considered but not proven. We did not have infor-
mation about those VTE events that were present on
admission compared to those that occurred during hos-
pitalization. We plan to conduct further validation stu-
dies in other databases where pre-existing diagnosis
modifiers are available. We cannot firmly establish caus-
ality between comorbidities and VTE using the data
available to us. Comorbidities may be linked to other
processes such as increased operative time or difficulty
weaning from a ventilator after surgery. Future research
with datasets containing these clinical variables may
clarify the exact causal pathway. Lastly, although in our
analysis we controlled for the presence of several factors
that might increase the risk of VTE, we did not have
data on the smoking status of individuals, which might
be related to both the exposure and outcome.
Conclusion
CHF is strongly associated with an increased risk of
VTE after THR and TKR; COPD is associated with an
increased risk of VTE after TKR. The absence of risk
associated with other comorbidities and co-occurring
comorbidities may be explained by the selection of heal-
thier older adults for these surgeries or by some of the
limiting factors described above. If these findings are
confirmed in other datasets, higher risk older adults
with comorbidities could potentially benefit from more
aggressive preventive interventions including high
potency pharmacologic prophylaxis.
Additional material
Additional file 1: Appendix I - ICD-9-CM Procedure and Diagnosis
Codes. total Joint Replacement Procedure Codes and Venous
Thromboembolism Diagnosis Codes.
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